4 withdrawn, 2 unknown, 1 completed, 1 suspended. 5 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 2, Withdrawn 2, Completed 1 |
| Phase 2 | 5 | Withdrawn 2, Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Suspended 1 |
Follow Antibody Therapy: new trials by email Literature Review of Antibody Therapy trials Research Report on Antibody Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Aldesleukin, Antibody Therapy, Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 2 | 2015-12-01 | 2023-05-15 |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-08-01 | 2007-08-14 |
| Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma cisplatin, cytarabine, etoposide - AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2006-02-01 | 2016-02-03 | |
| Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors monoclonal antibody anti-anb3 integrin, anti-cytokine therapy, antiangiogenesis therapy - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2002-02-01 | 2014-01-16 | |
| Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer antibody therapy, biological therapy, muromonab-CD3 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Unknown | St. Vincent Medical Center - Los Angeles | 1991-06-01 | 2013-11-06 | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma bortezomib, rituximab, antibody therapy - Lymphoma | Phase 2 | Terminated | University of Virginia | 46 | 2008-01-28 | |
| BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia BL22 immunotoxin, antibody therapy, biological response modifier therapy - Leukemia, Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2015-04-28 | ||
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer bevacizumab, gemcitabine hydrochloride, adjuvant therapy - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2015-04-28 | ||
| GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride - Lymphoma | Phase 3 | Suspended | Favrille | 480 | 2013-12-18 |
Lymphoma, Non-Hodgkin (4) · Lymphoma (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Pancreatic Neoplasms (2) · Burkitt Lymphoma (1) · Leukemia, Prolymphocytic (1) · Lymphoma, AIDS-Related (1) · Lymphoma, Large-Cell, Anaplastic (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Barbara Ann Karmanos Cancer Institute (2) · National Cancer Institute (NCI) (2) · AIDS Malignancy Consortium (1) · Cambridge Antibody Technology (1) · Favrille (1) · St. Vincent Medical Center - Los Angeles (1) · University of Virginia (1)
United States (6) · Poland (1)
Alexandra M. Levine, MD (1) · Anil Tulpule, MD (1) · Anthony Shields (1) · Charles L. Wiseman, MD, FACP (1) · John Densmore, MD (1) · John F. Bender, PharmD (1) · Patricia LoRusso, DO (1) · Richard E. Royal, MD, FACS (1) · Robert Kreitman, MD (1)
P30CA022453 (1)